Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04629495 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rapamycin - Effects on Alzheimer's and Cognitive Health

Study acronym: REACH
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Mar 2026 to Mar 5, 2026
    • Study completion date: Mar 2026 to Mar 5, 2027
    • Site details revised
    v14
  2. Site contact updated
    • Collaborators expanded, about 2 words
    v13
  3. Primary completion date: Dec 2024 to Mar 2026
    • Study completion date: Apr 2025 to Mar 2026
    v12
  4. Primary completion date: Jun 2024 to Dec 2024
    • Study completion date: Dec 2024 to Apr 2025
    v11
  5. Primary completion date: Dec 2023 to Jun 2024
    • Study completion date: Aug 2024 to Dec 2024
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. 3 versions Re-verified since Oct 10, 2022, no change to tracked fieldsv7-v9
  2. Start date changed from estimate of Aug 15, 2021 to Aug 11, 2021v6
  3. Start date: Jun 2021 to Aug 15, 2021v5
  4. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Aug 2022 to Dec 2023
    • Start date: Apr 2021 to Jun 2021
    • Study completion date: Aug 2023 to Aug 2024
    • Site details revised
  5. Start date: Jan 2021 to Apr 2021v3
  6. Primary endpoints revised (5)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).
Trial Details
NCT Number NCT04629495
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: Alzheimer's Association
Conditions
(from sponsor)		 Mild Cognitive Impairment, Alzheimer Disease
Related terms Alzheimer Disease, Cognitive Dysfunction
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov